Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Google Secures Pentagon AI Deal for Classified Projects 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
CAMBRIDGE, Mass., Feb. 17, 2016 -- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, February 24, 2016 at 8:30 AM ET to report its fourth quarter and full year 2015 financial results and discuss recent business updates.
The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 49865237. A replay of the webcast will be available on Sage’s website approximately two hours after the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. Sage is developing its next generation modulators, including SAGE-217, SAGE-689 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.
Investor Contact: Paul Cox, Sage Therapeutics [email protected] 617-299-8377 Media Contact: Maureen L. Suda, Suda Communications LLC [email protected] 585-387-9248
